Regulatory polymorphisms in CYP2C19 affecting hepatic expression

Drug Metabolism and Drug Interactions

Volumn 28, Issue 1, 2013, Pages 23-30

  Sanford, Jonathan C ^a   Guo, Yingying ^b   Sadee, Wolfgang ^a   Wang, Danxin ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Allelic expression imbalance; Biomarker; Clopidogrel; CYP2C19; Cytochrome P450; Polymorphism

Indexed keywords

4' HYDROXYMEPHENYTOIN; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450 2C19; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; PREGNANE X RECEPTOR; RETINOID X RECEPTOR ALPHA; TRANSCRIPTION FACTOR GATA 4;

ARTICLE; CONTROLLED STUDY; DNA ISOLATION; ENZYME ACTIVITY; EXON; GENE CONTROL; GENE EXPRESSION; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN TISSUE; LIVER; LIVER METABOLISM; LIVER MICROSOME; METABOLIC REGULATION; PROMOTER REGION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RNA ISOLATION; SINGLE NUCLEOTIDE POLYMORPHISM;

AFRICAN AMERICANS; ALLELES; ARYL HYDROCARBON HYDROXYLASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENETIC VARIATION; HUMANS; LIVER; POLYMORPHISM, SINGLE NUCLEOTIDE; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84877992788     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/dmdi-2012-0038     Document Type: Article

References (44)

1. Guengerich FP. Cytochrome p450 and chemical toxicology. Chem Res Toxicol 2008;21:70-83.
2. Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010;38:92-9.
3. Karam WG, Goldstein JA, Lasker JM, Ghanayem BI. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab Dispos 1996;24:1081-7.
4. Ohlsson Rosenborg S, Mwinyi J, Andersson M, Baldwin RM, Pedersen RS, Sim SC, et al. Kinetics of omeprazole and escitalopram in relation to the CYP2C19.*17 allele in healthy subjects. Eur J Clin Pharmacol 2008;64:1175-9.
5. The Human Cytochrome P450 (CYP) Allele Nomenclature Committee. The Human Cytochrome P450 (CYP) Allele Nomenclature Database. CYP2C19 allele nomenclature. Available at: http://www.cypalleles.ki.se/cyp2c19.htm. Accessed on 15 October 2012.
6. de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594-8.
7. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269:15419-22.
8. Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 2011;90:328-32.
9. The 1000 Genomes Project. 1000 Genomes Browser. Available at: http://browser.1000genomes.org. Accessed on 15 October 2012.
10. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-62.
11. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. J Am Med Assoc 2009;302:849-57.
12. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-Analysis. J Am Med Assoc 2010;304:1821-30.
13. Hwang SJ, Jeong YH, Kim IS, Koh JS, Kang MK, Park Y, et al. The cytochrome 2C19.*2 and.*3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention. Thromb Res 2011;127:23-8.
14. U.S Food and Drug Administration. Information on clopidogrel bisulfate (marketed as Plavix). Available at: http://www.fda. gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformation forPatientsandProviders/ucm190836.htm. Accessed on 17 September 2012.
15. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006;79:103-13.
16. Tiroch KA, Sibbing D, Koch W, Roosen-Runge T, Mehilli J, Schomig A, et al. Protective effect of the CYP2C19.*17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am Heart J 2010;160:506-12.
17. Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, et al. Cytochrome 2C19.*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogreltreated patients with coronary stent placement. Circulation 2010;121:512-8.
18. Pare G, Mehta SR, Yusuf S, Anand SS, Connolly SJ, Hirsh J, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 2010;363:1704-14.
19. Sibbing D, Gebhard D, Koch W, Braun S, Stegherr J, Morath T, et al. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. J Thromb Haemost 2010;8:1685-93.
20. Baldwin RM, Ohlsson S, Pedersen RS, Mwinyi J, Ingelman-Sundberg M, Eliasson E, et al. Increased omeprazole metabolism in carriers of the CYP2C19.*17 allele;a pharmacokinetic study in healthy volunteers. Br J Clin Pharmaco 2008;65:767-74.
21. Dolton MJ, McLachlan AJ. Clinical importance of the CYP2C19.*17 variant allele for voriconazole. Br J Clin Pharmaco 2011;71:137-8.
22. de Vos A, van der Weide J, Loovers HM. Association between CYP2C19.*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients. Pharmacogenomics J 2011;11:359-67.
23. Wang G, Lei HP, Li Z, Tan ZR, Guo D, Fan L, et al. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur J Clin Pharmacol 2009;65:281-5.
24. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4 '-hydroxylase in humans. Biochemistry 1994;33:1743-52.
25. Gawronska-Szklarz B, Adamiak-Giera U, Wyska E, Kurzawski M, Gornik W, Kaldonska M, et al. CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers. Eur J Clin Pharmacol 2012;68:1267-74.
26. Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-Analysis. Br Med J 2011;343:d4588.
27. Li Y, Tang HL, Hu YF, Xie HG. The gain-of-function variant allele CYP2C19.*17: a double-edged sword between thrombosis and bleeding in clopidogrel-Treated patients. J Thromb Haemost 2012;10:199-206.
28. Jang JS, Cho KI, Jin HY, Seo JS, Yang TH, Kim DK, et al. Meta-Analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel. Am J Cardiol 2012;110:502-8.
29. Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19.*17. Br J Clin Pharmaco 2010;69:222-30.
30. Satyanarayana Chakradhara Rao U, Devendran A, Satyamoorthy K, Shewade DG, Krishnamoorthy R, Chandrasekaran A. Functional characterization of promoter region polymorphisms of human CYP2C19 gene. Mol Biol Rep 2011;38:4171-9.
31. Fukushima-Uesaka H, Saito Y, Maekawa K, Ozawa S, Hasegawa R, Kajio H, et al. Genetic variations and haplotypes of CYP2C19 in a Japanese population. Drug Metab Pharmacok 2005;20:300-7.
32. Pedersen RS, Brasch-Andersen C, Sim SC, Bergmann TK, Halling J, Petersen MS, et al. Linkage disequilibrium between the CYP2C19.*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. Eur J Clin Pharmacol 2010;66:1199-205.
33. Lim JE, Pinsonneault J, Sadee W, Saffen D. Tryptophan hydroxylase 2 (TPH2) haplotypes predict levels of TPH2 mRNA expression in human pons. Mol Psychiatr 2007;12:491-501.
34. van der Hoeven TA, Coon MJ. Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase from rabbit liver microsomes. J Biol Chem 1974;249:6302-10.
35. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-75.
36. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J 2011;11:274-86.
37. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C > T affects mRNA stability. Pharmacogenet Genom 2005;15:693-704.
38. Pinsonneault J, Nielsen CU, Sadee W. Genetic variants of the human H + /dipeptide transporter PEPT2: analysis of haplotype functions. J Pharmacol Exp Ther 2004;311:1088-96.
39. Blaisdell J, Mohrenweiser H, Jackson J, Ferguson S, Coulter S, Chanas B, et al. Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenet Genom 2002;12:703-11.
40. Barber RD, Harmer DW, Coleman RA, Clark BJ. GAPDH as a housekeeping gene: analysis of GAPDH mRNA expression in a panel of 72 human tissues. Physiol Genomics 2005;21:389-95.
41. Baker JA, Weber J, Felke E, Price R, Hall SD, Hillgren K, et al. Characterization of a human liver bank as a tool for research in pharmacogenetics (PGx). Clin Pharmacol Ther 2011;89(Supp1):S75.
42. Mwinyi J, Hofmann Y, Pedersen RS, Nekvindova J, Cavaco I, Mkrtchian S, et al. The transcription factor GATA-4 regulates cytochrome P4502C19 gene expression. Life Sci 2010;86:699-706.
43. Chen Y, Ferguson SS, Negishi M, Goldstein JA. Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter. Mol Pharmacol 2003;64:316-24.
44. Furukawa M, Nishimura M, Ogino D, Chiba R, Ikai I, Ueda N, et al. Cytochrome p450 gene expression levels in peripheral blood mononuclear cells in comparison with the liver. Cancer Sci 2004;95:520-9.